HOME >> BIOLOGY >> NEWS
Doctors failure to reevaluate asthma severity hurts wheezing sufferers

Doctors who do not periodically reevaluate their patients' asthma severity are failing to provide good care to asthma sufferers, report Johns Hopkins physicians May 20 at the American Thoracic Society's annual meeting.

"We found that doctors were not reevaluating their patient's underlying asthma severity estimates and that these estimates anchor their treatment decisions," says Gregory Diette, M.D., an assistant professor of pulmonary and critical care medicine at Hopkins. "Doctors need to frequently update their severity assessments in order to provide care that meets the patient's needs."

According to most treatment guidelines, doctors should base asthma therapy on an individual's symptoms prior to medication use, a profile known as underlying severity estimate. But how physicians' estimates influenced care has been a black box. To examine the issue, the Hopkins team gathered data from 1,510 patients who had moderate asthma, as determined by self-reported symptoms and treatment guidelines. Through surveys, they discovered that their doctors had classified 849 of them as having an underlying severity estimate of mild; they deemed the other 761 as moderate or greater.

When the researchers compared the two groups with National Asthma and Education Prevention Program (NAEPP) guidelines, they found that the lower the estimate, the worse the care. Doctors gave many more moderately asthmatic patients guidance and information about how to manage their symptoms and handle an attack, in comparison to mild asthmatics. Roughly 60 percent of the moderate cases, for example,had a peak flow meter, a device patients use frequently to measure lung capacity and adjust anti-asthma drugs to prevent severe episodes. Only 16 percent of the mildly asthmatic patients owned these devices.

"Doctors need to reevaluate patients periodically to ensure an accurate, up-to-date diagnosis, and ensure quality treatment," says Linda Wolfenden, M.D., presenter of the study
'"/>

Contact: Kate O'Rourke
korourke@jhmi.edu
410-955-8665
Johns Hopkins Medical Institutions
19-May-2001


Page: 1 2

Related biology news :

1. Doctors miss chances to help pregnant women quit smoking
2. Doctors miss chance to advise women of vitamin that prevents birth defects, survey finds
3. Doctors perform more IVF treatments, but multiple births decline
4. Doctors aware of Tylenol-related liver risk - but is the public getting the message?
5. One In Three Doctors Recommends Herbal Supplements To Patients
6. Doctors Find Lead On Common Genes Which Can Lead To Bowel Cancer
7. Plant Doctors Find Genetic Solution For Papaya Growers
8. Phase Out Planned For One Of Top Five U.S. Pesticides, Plant Doctors Respond
9. New Heart-Attack Indicator Dramatically Improves Diagnostic Accuracy Of ER Doctors: TnT/Echocardiogram Combination Could Reduce Needless Admissions
10. Pump failure implicated in a form of dystonia
11. UCSD finds genetic time bomb in heart that leads to heart failure in some patients

Post Your Comments:
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... July 30, 2015 after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:7/8/2015)... YORK , July 8, 2015  BD (Becton, ... BD & Guidepoint Mentor, a new program ... Guidepoint,s expert network services. BD is ... to improve healthcare delivery and outcomes and, with the ... entrepreneur will be able to directly engage with industry ...
(Date:7/7/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a biometric ... revised version of one of its first 30 second commercials will ... New York , Chicago , ... metro areas.    , , , , ... the cards in your wallet and keep your identity secure. ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
(Date:7/29/2015)... Inc. (NYSE: BIOA ) today announced that ... resigned.  The Company has hired Andrew Ashworth , ... 2014, as full time interim CFO and has launched ... Andy Ashworth began his employment today, to overlap ... was the Company,s CFO from September 2011 to December ...
(Date:7/29/2015)... July 29, 2015 ... the addition of the "Global Biosimilars Market, ... The Global Biosimilars Market, 2015 - ... rapidly growing biosimilars market. With the blockbuster biologics ... minimize costs, biosimilars are being viewed as viable ...
(Date:7/29/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) announced today ... released on Thursday, August 13, 2015, before the open ... will host a conference call to discuss the financial ... outlining the financial results and business update will be ... call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
Cached News: